Applied Filters
Life sciences lawyers shocked and concerned amid Brexit uncertainty
Lawyers have told LSIPR they are concerned about the continuing UK political uncertainty having a negative impact on life sciences investment and the Unified Patent Court.
Sanofi collaborates with Biomunex to develop antibody therapeutics
Multinational pharmaceutical company Sanofi has entered into a licensing agreement with Paris-based biopharmaceutical company Biomunex.
UK publishes further no-deal Brexit guidance for medicines
The UK government has published further guidance on the regulation of medicines, medical devices and clinical trials in the event of a no-deal Brexit.
GSK and Pfizer sign joint venture, but will demerge after three years
Pharmaceutical companies GSK and Pfizer yesterday announced that they will combine their consumer health businesses into a new joint venture with sales of approximately £9.8 billion ($12.7 billion).
Eli Lilly collaborates with AC Immune to develop Alzheimer’s treatment
Global pharmaceutical company Eli Lilly has entered into a licence and collaboration agreement with Swiss biotechnology company AC Immune.
AstraZeneca to launch CRISPR-based cancer research centre
Pharmaceutical company AstraZeneca and charity Cancer Research UK have announced that they will launch a centre to accelerate the discovery of new cancer treatments.
Appeal filed against EPO sofosbuvir patent decision
Six organisations have appealed against the European Patent Office’s decision to uphold a patent for a key hepatitis C drug.
European pharma body criticises SPC waiver vote
The European Federation of Pharmaceutical Industries and Associations has sharply criticised an opinion on supplementary protection certificate proposals that was issued by a European Parliament committee.
UK life sciences partnership to use AI in disease detection
The UK government and the life sciences industry have partnered to develop new technology using artificial intelligence to detect diseases at an early stage.
Boehringer in research collaboration with Domain Therapeutics
German pharmaceutical company Boehringer Ingelheim has signed a research collaboration and licence agreement with French and Canadian biopharmaceutical business Domain Therapeutics.
